Sarepta Therapeutics Inc said the U.S.
meals and Drug administration had delayed a decision on its lead drug for a
unprecedented muscle-losing disorder.
The FDA has delayed the decision to may additionally 26 from
past due February, the organisation stated.
The drug is designed to deal with a subset of patients with
Duchenne muscular dystrophy.
The organization in past due January postponed a assembly of
its advisory panel to check Sarepta's drug due to inclement weather forecast
for Washington DC.
No comments:
Post a Comment